Press Releases April 21, 2026 09:00 AM

Gevo to Report First Quarter 2026 Financial Results on May 7, 2026

Gevo Announces Q1 2026 Financial Results Conference Call for May 7

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
GEVO

Gevo, Inc., a diversified renewable energy company listed on NASDAQ as GEVO, announced it will report its first quarter 2026 financial results on May 7, 2026, with a live conference call scheduled to discuss the earnings. The company focuses on sustainable fuels and renewable products, operating key facilities in ethanol, carbon capture, renewable natural gas, and specialty jet fuel production, aiming to support energy security and rural economic growth.

Gevo to Report First Quarter 2026 Financial Results on May 7, 2026
GEVO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Gevo will report Q1 2026 financial results on May 7 with an investor conference call.
  • Gevo operates multiple renewable energy and sustainable fuel production facilities, including ethanol with carbon capture, dairy-based renewable natural gas, and alcohol-to-jet fuel production.
  • The company emphasizes its role in energy security, carbon abatement, and strengthening rural economies through innovative and sustainable technologies.

ENGLEWOOD, Colo., April 21, 2026 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) today announced it will host a conference call at 4:30 p.m. ET (2:30 p.m. MT) Thursday, May 7 to report its financial results for the first quarter that ended March 31.

To participate in the live call, please call (800) 715-9871 (U.S. toll-free) or (646) 307-1963 (international). Please reference passcode 3527252 to join the call.

To listen to the conference call (audio only, non-participating), please register through the following event weblink: https://edge.media-server.com/mmc/p/mngys3a9  

A webcast replay will be available after the conference call ends on May 7. The archived webcast will be available in the Investor Relations section of Gevo's website at investors.gevo.com.

About Gevo 
Gevo is a next-generation diversified energy company committed to fueling America’s future with cost-effective, drop-in fuels that contribute to energy security, abate carbon, and strengthen rural communities to drive economic growth. Gevo’s innovative technology can be used to make a variety of renewable products, including sustainable aviation fuel (“SAF”), motor fuels, chemicals, and other materials that provide U.S.-made solutions. Gevo’s business model includes developing, financing, and operating production facilities that create jobs and revitalize communities. Gevo owns and operates an ethanol plant with an adjacent carbon capture and sequestration (“CCS”) facility and Class VI carbon-storage well. Gevo also owns and operates one of the largest dairy-based renewable natural gas (“RNG”) facilities in the United States, turning by-products into clean, reliable energy. Additionally, Gevo developed the world’s first production facility for specialty alcohol-to-jet (“ATJ”) fuels and chemicals operating since 2012. Gevo is currently developing the world’s first large-scale ATJ facility to be co-located at our North Dakota site. Gevo’s market-driven “pay-for-performance” approach regarding carbon and other sustainability attributes helps deliver value to our local economies. Through its Verity subsidiary, Gevo provides transparency, accountability, and efficiency in tracking, measuring, and verifying various attributes throughout the supply chain. By strengthening rural economies, Gevo is working to secure a self-sufficient future and to make sure value is brought to the market.

For more information, see www.gevo.com.

MEDIA CONTACT
[email protected] 

IR CONTACT
[email protected] 


Risks

  • Financial results may not meet investor expectations impacting stock performance.
  • Operations in emerging sustainable fuel markets may face regulatory and market acceptance uncertainties.
  • Project development and scaling of large facilities could face execution risks affecting production and profitability.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026